Microbiotica reported positive Phase Ib data for MB‑310, an oral live biotherapeutic targeting ulcerative colitis. In the study, 12 of 19 treated patients achieved clinical remission versus three of 10 in the placebo arm; responders sustained remission and resolution of rectal bleeding during a three‑month follow‑up. The trial also showed histological improvements and mucosal biomarker changes in responders. Microbiotica plans to advance MB‑310 into later‑stage studies to validate efficacy, durability, and safety across broader UC populations. The data add to growing clinical interest in live microbiome therapeutics for inflammatory bowel disease, highlighting potential for oral modalities to induce mucosal healing with favorable tolerability compared with systemic immunosuppressants.